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the proportion of patients treated for RLS in a large claims data-
base. METHODS: We identiﬁed patients with at least one RLS
diagnosis (ICD-9 333.99) between 1999 and 2003 in Medstat’s
MarketScan Commercial Claims and Encounters database of de-
identiﬁed insurance claims from employees and dependents. We
estimated treated RLS by calculating the proportion of patients
in the database with a ﬁrst-time RLS diagnosis (incidence) and
with an RLS diagnosis anytime (prevalence). RESULTS: Inci-
dence of RLS treatment increased slightly each year, from 0.3402
per 1,000 persons in 1999 to 0.4494 per 1,000 in 2003. Preva-
lence also rose, reaching 0.5414 per 1,000 in 2003. Prevalence
rates per 1,000 in 2003 by age group were: ages 1–17, 0.0330;
ages 18–34, 0.1845; ages 35–44, 0.5848; ages 45–54, 1.0049;
and ages 55–64, 1.3069. Prevalence for women per 1,000 was
0.6576 compared to 0.4126 for men. US geographic regions with
the highest rates were North Central (0.6842) and South
(0.5686), with lower rates seen in Northeast (0.4074) and West
(0.4172). Higher rates of RLS (1.8621 vs. 0.3259 per 1000) were
found among patients who had any characteristic that put them
at “high risk” for RLS (anemia, end-stage renal disease, diabetes,
rheumatoid arthritis, pregnancy or SSRI use). CONCLUSIONS:
Rates of treated RLS were higher among older patients, women,
and those with “high risk” factors, consistent with previous
research. Compared to RLS prevalence estimates from popula-
tion-based studies, rates were low in our sample. Additional
research may help to understand the large differences in these
prevalence estimates.
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HOSPITAL LENGTH OF STAY ASSOCIATED WITH
ANTICONVULSANT UTILIZATION BY PATIENTS WITH
SEIZURE DISORDERS IN THE U.S.
Blanchette CM, Stemkowski S, Craver C,Wang PF, Saunders W
Premier, Inc, Charlotte, NC, USA
OBJECTIVES: Comparing length of stay by anticonvulsant
therapy may be the ﬁrst step to identifying adverse events asso-
ciated with treatment as well as treatment effectiveness. This
study attempts to determine the association between the hospi-
tal length of stay and the use of anticonvulsants by inpatients
with seizure disorders. METHODS: A cohort of 126,362
patients admitted to U.S. hospitals from July 1, 2004 to June 30,
2005 with a diagnosis of seizure or epilepsy was constructed
using data from Premier’s Perspective Comparative Database.
Anticonvulsant use was tracked throughout each patient’s 
hospital stay and patients were categorized by drug into carba-
mazepine, clonazepam, divaloprex, fosphenytoin, gabapentin,
lamotrigine, magnesium, oxcarbazepine, phenytoin, topiramate,
valproic acid, levetiracetam, and other anticonvulsants groups.
Descriptive statistics including demographic characteristics and
drug utilization were reported for the sample. Mixed regression
models were used to control for selection bias due to patient clus-
tering within hospitals. The model observed the impact of anti-
convulsant monotherapy by drug on length of stay. RESULTS:
Mean length of stay for non-users were 5.63 (SD = 9.02) and
drug users ranged between topiramate users with 5.42 (SD =
6.20) and magnesium users with 12.99 (SD = 18.27). Clon-
azepam (t = 5.41, p < 0.0001), divaloprex (t = 5.09, p < 0.0001),
gabapentin (t = 7.25, p < 0.0001), magnesium (t = 40.76, p <
0.0001) and phenytoin (t = 7.58, p < 0.0001) were signiﬁcantly
associated with length of stay while controlling for race, gender,
age, severity of illness and admission status. CONCLUSIONS:
Further analysis should investigate patterns of events associated
with increased length of stay in patients taking clonazepam,
divaloprex, gabapentin, magnesium, and phenytoin for identiﬁ-
cation of potential adverse events.
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COMPARING THE RELATIVE COST-EFFECTIVENESS OF ORAL
PROPHYLACTIC MEDICATION VS. BOTULINUM TOXIN TYPE A
(BOTOX®) IN THE MANAGEMENT OF MIGRAINE HEADACHE:
A MODEL EVALUATING THE CLINICAL AND ECONOMIC
IMPACT OF CURRENT TREATMENT OPTIONS
Goldberg LD
Goldberg, MD & Associates, Battle Ground, WA, USA
OBJECTIVES: The oral prophylactic medications currently uti-
lized in the management of migraine headache have been shown
to exhibit varying responsiveness in terms of reduction of
headache burden. It is the objective of this model to be used as
tool to compare the relative cost-effectiveness (CE) of these
agents vs. botulinum toxin type A (BOTOX®/BTX-A) from a
payer perspective. METHODS: An interactive Excel-based
model was developed to compare the relative CE of the avail-
able oral prophylactic medications vs. BTX-A in the treatment
of migraine headache. Drug effectiveness with respect to reduc-
tion in headache burden and utilization of acute medications was
based on the published literature. Drug costs were based on
average wholesale price with consideration of contractual dis-
counts and patient co-payment. The primary economic end-
points were the drug cost per headache (HA) and headache day
(HAD) for episodic migraine and chronic migraine respectively.
Multi-factor sensitivity analyses were conducted. RESULTS: In
the management of episodic migraine, the oral prophylactic 
medications offered a cost per HA avoided varying from US$48
(divalproex sodium/Depakote®) to US$138 (gabapentin/
Neurontin®). In the management of chronic migraine, BTX-A
offered a cost per HAD avoided of US$17. Total migraine related
drug costs (inclusive of both acute and prophylactic medications)
were found to be unchanged with the utilization of BTX-A due
to the offsetting reduction in acute medication use associated
with BTX-A therapy. CONCLUSION: Modeling CE in terms of
reduction in headache burden provides a methodology for com-
paring clinical trials and demonstrates that the relative difference
in CE between the oral prophylactic medications and BTX-A in
the management of migraine headache is signiﬁcant.
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OBJECTIVES: Clinical trials establishing the efﬁcacy of disease
modifying drugs (DMDs) utilized in treating relapsing forms of
Multiple Sclerosis (MS) have been based on populations of
varying baseline relapse rates and disability burden. It is the
objective of this model to be used as a tool to compare the 
relative cost-effectiveness (CE) of these drugs from a payer 
perspective. METHODS: An interactive Excel-based model was
developed to compare the relative cost components of relapses,
disability progression, and DMDs in the treatment of MS. Drug
effectiveness with respect to reduction in relapses and the
slowing of disability progression was derived from the published
Level I clinical trial data and was based on absolute risk reduc-
tion (ARR) in clinical events to account for differences between
study populations. Cost data was based on work by O’Brien and
colleagues, and disability progression data was based on research
by Weinshenker and colleagues. Drug costs were based on
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wholesale acquisition cost with consideration of contractual dis-
counts and patient co-payment. The primary economic endpoint
was cost per relapse avoided over a 4-year period of treatment.
RESULTS: The ARR varied across the ﬁve DMDs with inter-
feron beta-1a SC injection (Rebif®) showing the highest results
(0.72) and interferon beta-1a IM injection (Avonex®) the lowest
(0.26). Economic results showed signiﬁcant difference in the
cost-effectiveness ratio (CER) among the DMDs, with interferon
beta-1a SC injection (Rebif®) having the most favorable CER
(US$47958/relapse avoided) and interferon beta-1a IM injection
(Avonex®) having the least favorable (US$121,147/relapse
avoided). Interferon beta-1b SC injection (Betaseron®), 
glatiramer acetate SC injection (Copaxone®), and natalizumab
IV injection (Tysabri®) offer intermediate CER results of
US$48,345, US$68,440, and US$93,903 per relapse avoided,
respectively. CONCLUSION: Modeling absolute reduction 
in clinical endpoints provides a methodology for comparing 
clinical trials and demonstrates that the difference in cost-
effectiveness results among the DMDs is signiﬁcant.
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EXAMINATION OF THE COST-EFFECTIVENESS OF DOPAMINE
AGONISTS FOR THE TREATMENT OF RESTLESS LEGS
SYNDROME
Beard AJ
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OBJECTIVE: To examine the cost-effectiveness of ropinirole for
the treatment of primary restless legs syndrome (RLS) versus the
alternative off-label therapies of pramipexole and pergolide.
METHODS: A cost-effectiveness analysis was conducted from
the societal perspective using a cohort of 10,000 United States
adults 45 years old and older with moderate-to-severe primary
RLS. A decision tree was used to model cost-effectiveness for a
two-year period following commencement of dopamine agonist
therapy. Outcome probabilities were obtained from a systematic
review of randomized controlled trials and observational studies.
Costs were derived from standard 2005 health care cost refer-
ences. Cost-effectiveness decision models were created for base-
case analyses. One-way and probabilistic sensitivity analyses
were conducted to test the robustness of the ﬁndings. RESULTS:
In terms of changes in the International Restless Legs Syndrome
Study Group Rating Scale (IRLS) score for RLS severity, per-
golide dominates ropinirole given the base-case. Pergolide is 
cost-saving when compared to both ropinirole and pramipexole,
resulting in a saving of $1687 and $556 per one-point improve-
ment in IRLS score. One-way sensitivity analyses indicated that
the IRLS scores for augmentation strongly inﬂuenced the calcu-
lated incremental cost effectiveness ratios (ICERs). Probabilistic
sensitivity analyses revealed variation in the results indicating a
lack of clear dominance. CONCLUSIONS: None of the thera-
pies is clearly dominant in terms of cost per IRLS score change.
Although ropinirole is currently the only U.S. Food and Drug
Administration (FDA) approved medication for the treatment of
RLS, it is not more cost-effective than alternate off-label
dopamine agonists prescribed for RLS.
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OBJECTIVE: To determine the effect of neutralizing antibodies
(NAbs) on the cost-effectiveness of disease-modifying agents
(DMAs) used to treat multiple sclerosis (MS). METHODS: A
cost-effectiveness model was developed using relapse rate and
disability progression endpoints from pivotal phase III trials of
currently approved DMAs for MS (interferon beta [IFNB]-1a IM
[Avonex], IFNB-1a SC [Rebif], IFNB-1b [Betaseron], and glati-
ramer acetate [GA; Copaxone]). The model was created from a
managed care perspective with time horizons of 24 and 48
months. Cost-effectiveness is expressed as a ratio of total uti-
lization costs per percent relative risk reduction for relapses and
disability progression; daily cost-effectiveness is shown as per
percentage point reduction. The incidence of NAbs and their
effect on efﬁcacy was obtained from prescribing information,
open-label extension studies of IFNB products, and a large pop-
ulation study. The model includes the following assumptions:
comparison of similar endpoints across different clinical trials;
constant adverse event rates among products; constant burden
of relapse over time; constant persistence/compliance rates
among products; similar laboratory testing/frequency among
IFNB products. A one-way sensitivity analysis was conducted to
test the robustness of the model to changes in NAb incidence.
RESULTS: At 24 months, the cost-effectiveness for disability
progression was $824 ($1.13/day) for IFNB-1a IM, $1222
($1.67/day) for IFNB-1a SC, $1150 ($1.57/day) for IFNB-1b,
and $2558 ($3.50/day) for GA. After the development of NAbs,
at 48 months cost-effectiveness was $1659 ($1.14/day) for
IFNB-1a IM, $2536 ($1.74/day) for IFNB-1a SC, $2433
($1.67/day) for IFNB-1b, and $5117 ($3.50/day) for GA. Results
were similar for relapse rate. Results of sensitivity analyses 
conﬁrmed the robustness of the model. CONCLUSIONS: NAbs
reduce the cost-effectiveness of IFNB products. IFNB-1a IM
(Avonex) was the most cost-efﬁcacious DMA before (24 months)
and after (48 months) the development of NAbs.
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OBJECTIVES: Using long-term follow-up data from clinical
trials, this analysis assesses the cost-effectiveness of ﬁve treat-
ment strategies in patients diagnosed with relapsing-remitting
multiple sclerosis (RRMS): symptom management alone (SMA)
and symptom management combined with subcutaneous glati-
ramer acetate (SCGA), intramuscular interferon beta-1-a (IM-
IFNb1-a), subcutaneous interferon beta-1-a (SC-IFNb1-a), or
subcutaneous interferon beta-1-b (SC-IFNb1-b). METHODS: A
literature-based Markov model was developed to assess the cost-
effectiveness of ﬁve treatment strategies for managing a hypo-
